EPISODE · Jan 12, 2026 · 1H 5M
Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50
from Flot.bio x Philip Hemme · host Flot.bio
Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and how Europe’s biotech space can rival those of the US and China.---Learn more about Transgene: https://bit.ly/tg_flotbio---⭐️ ABOUT THE SPEAKERAlessandro became Transgene’s CEO in 2023 after joining in 2022 as Chairman of the Board of Directors. He also played a key role in Gilead Sciences’ acquisition of Kite Pharma and the regulatory approval of the CAR-T therapy Yescarta. 🔗 LINKS MENTIONEDTransgene’s website - https://www.transgene.fr/Transgene’s €105 million fundraising - https://www.globenewswire.com/news-release/2025/11/26/3195422/0/en/Transgene-Successfully-Completes-a-Fundraising-of-c-105-Million.htmlFDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neckGilead Sciences’ acquisition of Kite Pharma for $11.9 billion - https://www.gilead.com/news/news-details/2017/gilead-sciences-to-acquire-kite-pharma-for-119-billionJohnson & Johnson’s collaboration and license deal withLegend Biotech - https://www.jnj.com/media-center/press-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-chinese-company-legend-biotech-to-develop-investigational-car-t-anti-cancer-therapy📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/alessandro-riva-transgene-cancer-vaccines/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:02] Transgene, the French biotech heavyweight[00:04:55] Standout personalized cancer vaccine[00:25:33] Transgene’s €105 million fundraising [00:32:05] Catalysts and oncolytic viruses
What this episode covers
Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and how Europe’s biotech space can rival those of the US and China.---Learn more about Transgene: https://bit.ly/tg_flotbio---⭐️ ABOUT THE SPEAKERAlessandro became Transgene’s CEO in 2023 after joining in 2022 as Chairman of the Board of Directors. He also played a key role in Gilead Sciences’ acquisition of Kite Pharma and the regulatory approval of the CAR-T therapy Yescarta. 🔗 LINKS MENTIONEDTransgene’s website - https://www.transgene.fr/Transgene’s €105 million fundraising - https://www.globenewswire.com/news-release/2025/11/26/3195422/0/en/Transgene-Successfully-Completes-a-Fundraising-of-c-105-Million.htmlFDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neckGilead Sciences’ acquisition of Kite Pharma for $11.9 billion - https://www.gilead.com/news/news-details/2017/gilead-sciences-to-acquire-kite-pharma-for-119-billionJohnson & Johnson’s collaboration and license deal withLegend Biotech - https://www.jnj.com/media-center/press-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-chinese-company-legend-biotech-to-develop-investigational-car-t-anti-cancer-therapy📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/alessandro-riva-transgene-cancer-vaccines/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:02] Transgene, the French biotech heavyweight[00:04:55] Standout personalized cancer vaccine[00:25:33] Transgene’s €105 million fundraising [00:32:05] Catalysts and oncolytic viruses
NOW PLAYING
Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50
No transcript for this episode yet
Similar Episodes
May 14, 2026 ·360m
May 14, 2026 ·310m
May 14, 2026 ·205m
May 14, 2026 ·85m
May 14, 2026 ·282m